Belimumab (Benlysta) — CPB 0818 | AETNA Coverage Update

Aetna modified CPB 0818 for belimumab (Benlysta), effective January 5, 2026. Here's what billing teams need to know.

Aetna, a CVS Health company, updated its coverage policy for belimumab (Benlysta) under CPB 0818 Aetna system. The primary billing code for this drug is HCPCS J0490 (Injection, Belimumab, 10 mg), administered via CPT 96365 for IV infusion or CPT 96372 for subcutaneous injection. This policy governs commercial medical plan coverage for two indications: systemic lupus erythematosus (SLE) and active lupus nephritis. If your practice bills Benlysta infusions or manages prior authorization for SLE patients, this update directly affects your reimbursement and claim denial risk.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Belimumab (Benlysta) — CPB 0818
Policy Code	CPB 0818
Change Type	Modified
Effective Date	January 5, 2026
Impact Level	High
Specialties Affected	Rheumatology, Nephrology, Infusion Centers, Specialty Pharmacy
Key Action	Verify autoantibody documentation and concurrent standard therapy before submitting precertification requests on or after January 5, 2026

---

Aetna Belimumab Coverage Criteria and Medical Necessity Requirements 2026

The Aetna belimumab coverage policy under CPB 0818 covers two indications. Each one has its own set of medical necessity criteria. Meet every criterion or expect a denial.

Systemic Lupus Erythematosus (SLE)

For active SLE, Aetna requires both of the following before approving belimumab billing:

#	Covered Indication Copy
1	The member must test positive for autoantibodies relevant to SLE before starting therapy. Acceptable markers include ANA, anti-dsDNA, anti-Sm, antiphospholipid antibodies, or complement proteins. Use CPT 0312U for the 8-IgG autoantibody panel, or individual serology codes like 86146 (Beta 2 Glycoprotein I antibody), 86147 (Cardiolipin antibody), 86148 (Anti-phosphatidylserine antibody), 86160–86162, or 86171 for complement testing.
2	The member must already be on a standard SLE treatment. That means glucocorticoids (e.g., prednisone billed as J7512, methylprednisolone as J1020 or J7509), antimalarials like hydroxychloroquine, or immunosuppressants (azathioprine J7500/J7501, methotrexate J8610–J8612, mycophenolate J7517/J7519, cyclosporine J7502/J7515/J7516, or cyclophosphamide).

Belimumab is an add-on therapy. It doesn't replace standard treatment—it runs alongside it. If your documentation doesn't show an active concurrent regimen, prior authorization will fail.

Active Lupus Nephritis

For lupus nephritis, Aetna's medical necessity standard is similar but has one important difference. The autoantibody requirement can be satisfied either by positive serology or by kidney biopsy confirming the diagnosis. Use CPT 50200 (percutaneous renal biopsy) or CPT 50205 (open surgical biopsy) to document the biopsy route if that's what your team has.

The standard therapy requirement for lupus nephritis mirrors SLE: the member must be on cyclophosphamide, mycophenolate mofetil, azathioprine, or glucocorticoids.

Continuation of Therapy

Reauthorization requires evidence of positive clinical response. Specifically, Aetna wants documentation of low disease activity or improvement in signs and symptoms. "The patient is tolerating the drug well" won't cut it. Pull objective measures — SLEDAI scores, proteinuria levels, serologic markers — before you submit.

Prior Authorization Requirements

Precertification is mandatory for all Aetna participating providers and members in applicable plan designs. Call (866) 752-7021 or fax (888) 267-3277. Statement of Medical Necessity forms are available through Aetna's Specialty Pharmacy Precertification portal. Missing prior authorization before the infusion is the fastest path to a claim denial with no recourse.

Also note: Aetna's Site of Care Utilization Management Policy applies to belimumab infusions. Before scheduling an infusion at a hospital outpatient department or physician office, confirm the approved site of service. The wrong site triggers a denial even when the clinical criteria are fully met.

---

Aetna Belimumab Exclusions and Non-Covered Indications

Two absolute exclusions apply under this coverage policy. Either one disqualifies the member, full stop.

1. Severe active CNS lupus at initiation. If the member has active CNS lupus — including seizures attributed to CNS lupus, psychosis, organic brain syndrome, cerebritis, or CNS vasculitis — and that condition requires therapeutic intervention, belimumab cannot be initiated. This isn't a documentation problem you can work around. The drug is contraindicated at initiation for this population under CPB 0818.

2. Concurrent biologic therapy. Aetna will not cover belimumab when used in combination with any other biologic. Review the member's full medication list before submitting. Rituximab (J9312, J9311) and its biosimilars (Q5115, Q5119, Q5123) appear in the policy's related code list specifically because they're the biologics most likely to show up in an SLE patient's history. If rituximab is active, belimumab billing will be denied.

There's also a specific note on cyclophosphamide: J9070 is flagged as "not covered when used in combination with Benlysta." Other cyclophosphamide codes (J9073, J9074, J9075, J9076) appear as standard concomitant therapy — but J9070 specifically has a coverage restriction when billed alongside J0490. Flag this in your charge capture system.

All other indications for belimumab are classified as experimental, investigational, or unproven. This policy does not support off-label use.

---

Coverage Indications at a Glance

---

Aetna Belimumab Billing Guidelines and Action Items 2026

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Belimumab (Benlysta) Under CPB 0818

Covered HCPCS Code (When Selection Criteria Are Met)

Code	Type	Description Copy
J0490	HCPCS	Injection, Belimumab, 10 mg

Administration CPT Codes

Code	Type	Description Copy
96365	CPT	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial
96372	CPT	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular

Diagnostic / Laboratory CPT Codes

Standard Concomitant Therapy HCPCS Codes

Not Covered When Combined with Benlysta (J0490)

Key ICD-10-CM Diagnosis Codes

Note: The full ICD-10 list under CPB 0818 contains 212 codes. The table above reflects the diagnostic groups most relevant to SLE, CNS lupus, and lupus nephritis billing. Access the complete code list at the CPB 0818 policy source.

---